MedLife Group receives the approval of the Competition Council for the acquisition of 50 percent of Neolife shares

MedLife has completed the acquisition of a 50 percent stake in Neolife Romania’s oncology centers, following its approval by the Competition Council. It is the largest transaction initiated by MedLife last year.

Thus, MedLife Group consolidates its integrated diagnostic and oncological treatment services through the 4 Neolife medical centers in Bucharest (2), Iasi and Brasov that will offer Romanian patients state-of-the-art technology, international medical know-how provided by multidisciplinary teams, experts in the most advanced procedures of diagnosis and oncological treatment.

“MedLife’s strategic goal is to strengthen the oncology area through a holistic approach that ranges from cancer prevention, diagnosis and treatment, to ensuring the quality of life of the oncological patient. The advantage will be the unbeatable experience of Neolife to provide access to top personalized medical care”, mentioned Mihai Marcu, CEO of MedLife.

“Together with MedLife, we are becoming a benchmark for our approach and effectiveness in treating cancer. Both by expanding the medical infrastructure and increasing the accessibility of cancer patients to top services, but especially by ensuring the long-term quality of Romanian health. We are not in the most optimistic scenario in the oncological area with 95,000 new cancers and about 54,000 cancer deaths in 2021, with the pandemic leading to significant delays in diagnosis and treatment. But even if the expectation is to increase the number of patients diagnosed with cancer or in advanced stages, there is also a leap in research and innovation through which our state-of-the-art therapies provide effective weapons in the fight against cancer. In Romania we have a very well-established team of professionals led by Fabio Razzetto, our Country Manager “, said Ismail Dernek, CEO of MNT Healthcare Group.

Neolife Medical Center Romania, with a total of over 250 employees and collaborators, ended 2021 with a turnover of 110 million RON, increasing by 20 percent compared to 2020.

MedLife Group will continue its dynamic expansion strategy after acquiring 6 companies last year: CED Pharma (June 2021), Leti Pharm (June 2021), Monix Pharm (June 2021), Pharmachem Distribution (July 2021), which were already consolidated. They were joined in November last year by Neolife Medical Center. Also at the end of last year, the company announced the acquisition of the full shareholding package of OncoCard Hospital in Brasov, acquisition that is still subject to Competition Council approval.